Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · IEX Real-Time Price · USD
1.570
+0.020 (1.29%)
At close: Apr 25, 2024, 3:59 PM
1.600
+0.030 (1.91%)
After-hours: Apr 25, 2024, 6:04 PM EDT
Company Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.
It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics plc
| Country | Ireland |
| Founded | 2015 |
| IPO Date | May 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Corey N. Fishman |
Contact Details
Address: Fitzwilliam Court, 1st Floor, Leeson Close Dublin 2, L2 D02 YW24 Ireland | |
| Phone | (872) 225-6077 |
| Website | iterumtx.com |
Stock Details
| Ticker Symbol | ITRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001659323 |
| CUSIP Number | G6333L101 |
| ISIN Number | IE000TTOOBX0 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Corey N. Fishman | President, Chief Executive Officer and Director |
| Judith M. Matthews | Chief Financial Officer |
| Dr. Michael W. Dunne M.D. | Strategic Advisor and Director |
| Dr. Sailaja Puttagunta M.D. | Chief Medical Officer |
| Tom Loughman Ph.D. | Senior Vice President of Technical Operations |
| Louise Barrett | Senior Vice President of Legal Affairs and Secretary |
| Dr. Steven I. Aronin M.D. | Senior Vice President and Head of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 6, 2024 | 8-K | Current Report |
| Jan 31, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 30, 2024 | 8-K | Current Report |
| Jan 30, 2024 | 8-K | Current Report |
| Dec 29, 2023 | 8-K | Current Report |
| Dec 14, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 14, 2023 | DEF 14A | Other definitive proxy statements |